TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03433547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Surgical procedures of small gauge vitrectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limbal paracentesis
Description: Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gas injection
Description: Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peeling internal limiting membrane
Description: Peeling internal limiting membrane with forceps

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gas tamponade
Description: Filling the vitreous cavity with gas (C3F8, 14%)
Study: NCT05595200

Intervention type: DIAGNOSTIC_TEST
Intervention: Level III portable sleep study
Description: Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
Study: NCT00222976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
Study: NCT03920501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Critical Care
Description: Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
Study: NCT02971397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04091958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoralis myo-glandular flap reconstruction.
Description: Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
Study: NCT01899547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted rectal resection
Description: Arm I: Patients undergo laparoscopic-assisted rectal resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional open rectal resection
Description: Arm II: Patients undergo conventional open rectal resection.
Study: NCT02961270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
Study: NCT00283400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% human albumin
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% human albumin
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% human albumin
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% human albumin
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
Study: NCT04605536

Intervention type: OTHER
Group type: OTHER
Intervention: animation videos
Description: watch animation videos about capsule endoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: explanation about endoscopy endoscopy
Description: Give general explanations about endoscopy endoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: explanation about endoscopy endoscopy
Description: Give general explanations about endoscopy endoscopy
Study: NCT03379506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR FDC Tablet
Description: Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matched to EBR/GZR FDC tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir Oral Granules
Description: Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir Oral Granules
Description: Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
Study: NCT00980421

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
Study: NCT01603030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0,5% + prednisolone 1%
Description: 1 gtt, 4x/day, 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin/prednisolone combination
Description: 1 gtt, 4x/day, 15 days
Study: NCT04488848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bolus glucose
Description: bolus Glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: continuous clucose
Description: continuous clucose
Study: NCT01779713

Intervention type: GENETIC
Intervention: Case-control transcriptomic study
Description: No intervention

Intervention type: GENETIC
Intervention: Case-control transcriptomic study
Description: No intervention
Study: NCT03922633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.
Study: NCT01750632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Description: The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
Study: NCT03838562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with virtual reality
Description: Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard optokinetic stimulator or dynamic visual surround
Description: Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group.
Study: NCT01601808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once a day, continuously throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprelsa (vandetanib)
Description: Orally once a daily, continuously throughout the study.
Study: NCT04532918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
Study: NCT01082367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TOBI
Description: TOBI (tobramycin inhaled solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOBI
Description: TOBI (tobramycin inhaled solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04574388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open label placebo
Description: open label placebo pill
Study: NCT04151095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR Exercise Training
Description: Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
Study: NCT01820780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultations specialized to J7 and J14
Description: Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls in 6 months and 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone calls in 6 months and 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides levels at 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natriuretic peptides levels at 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation with the general doctor or the cardiologist to J30 with blood results

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation with the general doctor or the cardiologist to J30 with blood results
Study: NCT02931214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04134611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No injection of Hyaluronic acid
Description: No injection of Hyaluronic acid was done
Study: NCT01950780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
Study: NCT03807661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous deep vein arterialization
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimFlow System
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Study: NCT02880137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere
Description: Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RTMPE
Description: Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
Study: NCT02775136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study: NCT03416803

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT03195036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based ECD services
Description: Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
Study: NCT01624441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03928314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
Study: NCT02844517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
Study: NCT00104091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-38
Description: TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
Study: NCT04131049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI calculated by CC (CHGI)
Description: This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI calculated by CC (CLGI)
Description: This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI calculated by FII (FHGI)
Description: This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI calculated by FII (FLGI)
Description: This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
Study: NCT03437915

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NIBB: accuboost
Description: 28.5 Gy delivered in 5 daily fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Description: 4-12 weeks post NIBB